Trial site
Retina Associates of Michigan
Grand Blanc, Michigan 48439, United StatesNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 11 trial
- Phase 21 trial
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Recruiting1 trial
- Terminated1 trial
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.3 trials
- Genentech, Inc.2 trials
- Astellas Pharma Global Development, Inc.1 trial
- Gyroscope Therapeutics Limited1 trial
- Jaeb Center for Health Research1 trial
- and 1 more
Running trials
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773· Astellas Pharma Global Development, Inc.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028· Phase 3· Jaeb Center for Health Research· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854· Phase 1· Genentech, Inc.· Source
Active, not recruiting
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102· Phase 4· Genentech, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error